Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology Inc. (ACTC)

Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 10/25/2014 10:11:57 PM - Followers: 645 - Board type: Free - Posts Today: 11

Advanced Cell Technology, Inc. (ACTC)




Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662


Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing:

For more information visit



Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
ACTC News: Amended Annual Report (10-k/a) 04/29/2014 04:36:14 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#75576   Thanks. It helps the discussion. farviewhill 10/25/14 10:11:57 PM
#75575   Could very well be, but I truly don't farviewhill 10/25/14 10:05:15 PM
#75574   fairviewhill: Some references to the necessity or sharpei 10/25/14 09:14:44 PM
#75573   Expansion Fern Wood 10/25/14 08:05:16 PM
#75572   Dilution homeslice10 10/25/14 06:52:51 PM
#75571   It would certainly be very helpful for a farviewhill 10/25/14 04:51:27 PM
#75570   My knowledge of this chartist/technical approach sounds as farviewhill 10/25/14 04:23:03 PM
#75569   "Money will be flowing. Add to that the chuckanutman 10/25/14 02:37:08 PM
#75568 chuckanutman 10/25/14 11:13:23 AM
#75567   I'm for the alteza 10/25/14 02:05:40 AM
#75566   Some of those folks must have been born elysse1kittycat 10/25/14 01:08:47 AM
#75565   LOL I tell you its over my head... Killtoy 10/24/14 11:41:13 PM
#75564   Nope not from ACTC. Gastrodamas 10/24/14 11:40:02 PM
#75563   Also says its the work from scientist from Gastrodamas 10/24/14 11:35:28 PM
#75562 Gastrodamas 10/24/14 11:31:36 PM
#75561   Of course. I just don't like to Humbug 10/24/14 11:30:12 PM
#75560   Investor stem cell forum has substance.. TLD Gastrodamas 10/24/14 11:22:20 PM
#75559   Lol-I remember that episode of The Twilight Zone-that elysse1kittycat 10/24/14 11:21:22 PM
#75558   I do, it was a favorite.. We now Gastrodamas 10/24/14 11:17:19 PM
#75557 continue Gastrodamas 10/24/14 11:08:45 PM
#75556 old news info Gastrodamas 10/24/14 11:07:38 PM
#75555   Posts about stock manipulation and where stock price elysse1kittycat 10/24/14 11:07:00 PM
#75554   now it is a triple post. Bring Humbug 10/24/14 11:01:01 PM
#75553   Do you remember the lead-in to the Outer elysse1kittycat 10/24/14 10:36:17 PM
#75552   Double post. elysse1kittycat 10/24/14 10:36:17 PM
#75551   The way this is acting right now they Gastrodamas 10/24/14 09:19:00 PM
#75550   Count me in, as long as its Gastrodamas 10/24/14 09:15:32 PM
#75549   Quick way to tell if a stock will Gastrodamas 10/24/14 09:12:09 PM
#75548   If ever the saying "to expect the unexpected" elysse1kittycat 10/24/14 09:10:43 PM
#75547   Investors bought in March 9th 2009 which was Gastrodamas 10/24/14 09:08:30 PM
#75546   Your right, let it drop then bring the Gastrodamas 10/24/14 09:04:51 PM
#75545   Elysse - my thoughts exactly and is the alteza 10/24/14 07:26:42 PM
#75544   FULLER, I would need to know more about farviewhill 10/24/14 06:32:00 PM
#75543   I never said $6.25-are you perhaps confusing me elysse1kittycat 10/24/14 05:59:31 PM
#75542   So you think it will go down to 6.25 stock_risk 10/24/14 05:51:42 PM
#75541   While this information and discussion has been helpful, farviewhill 10/24/14 05:50:28 PM
#75540   It is not what did happen but will elysse1kittycat 10/24/14 05:49:56 PM
#75539   What did happen in 12 nov. I looked stock_risk 10/24/14 05:42:48 PM
#75538   Sounds like a blast. I have been building Auger08 10/24/14 04:18:53 PM
#75537   Again I agree. elysse1kittycat 10/24/14 04:11:29 PM
#75536   Haha, I still think we have a big Auger08 10/24/14 03:58:18 PM
#75535   Can't argue that. elysse1kittycat 10/24/14 03:56:04 PM
#75534   Buying shares of an OTC biotech is way Auger08 10/24/14 03:53:55 PM
#75533   I am not disagreeing with that and never elysse1kittycat 10/24/14 03:41:54 PM
#75532   That is at least a week away from happening interstate 10/24/14 03:35:27 PM
#75531   Are we there yet? rdfdr1 10/24/14 03:35:06 PM
#75530   You know I am far from being a elysse1kittycat 10/24/14 03:26:47 PM
#75529   Promising-piece of ACTC puzzle is hiring LeRoux Jooste. chuckanutman 10/24/14 03:09:20 PM
#75528   But it may go up before that stock_risk 10/24/14 03:04:57 PM
#75527   I will add after up listing. I don't guy3 10/24/14 02:07:45 PM